Hatteras Venture Partners — 2015 Investments
3 investments dated 2015 · listed companies and verified rows first · show all
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology.
BiotechHealthtechMedical DevicesAlpharetta, US
Mark Prausnitz(Director)Charles Deignan(Executive Officer)Glenn Noronha(Executive Officer)Daniel H. White(Executive Officer, Director)
BoardEvgeny Zaytsev(Director)Derek Yoon(Director)in
Board seatClay ThorpChristy Shaffer· per SEC Form D
Co-investorsHEALTHCARE ROYALTY PARTNERSMountain Group CapitalSolasta VenturesHatteras
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Board seatClay ThorpChristy Shaffer· per SEC Form D
Co-investorsLumira VenturesMountain Group CapitalRA CapitalSolasta Ventures
PhaseBio is a company focused on developing treatments for cardiovascular disease, which is a leading cause of death in the United States.
BiotechHealthtechMedical DevicesMalvern, US
Ashutosh Chilkoti(Director)Joel Sussman(Executive Officer)Jonathan Mow(Executive Officer, Director)
BoardJames Barrett(Director)Michael Gutch(Director)Justin Klein(Director)
Board seatRobert IngramClay Thorp· per SEC Form D
Co-investorsMountain Group CapitalNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.